Breaking News Instant updates and real-time market news.

AFMD

Affimed NV

$2.15

-0.15 (-6.52%)

, BPTH

Bio-Path Holdings

$1.28

-0.03 (-2.29%)

07:52
11/29/16
11/29
07:52
11/29/16
07:52

Oppenheimer to hold a summit

Life Sciences Summit is being held in New York on November 29.

AFMD

Affimed NV

$2.15

-0.15 (-6.52%)

BPTH

Bio-Path Holdings

$1.28

-0.03 (-2.29%)

CHMA

Chiasma

KURA

Kura Oncology

$5.05

-0.3 (-5.61%)

EIGR

Eiger BioPharmaceuticals

$12.50

-0.5 (-3.85%)

MRNS

Marinus Pharmaceuticals

$1.11

-0.05 (-4.31%)

NERV

Minerva

$13.55

-0.45 (-3.21%)

OVAS

OvaScience

$3.58

-0.19 (-5.04%)

SCLN

SciClone

$10.25

0.05 (0.49%)

SPHS

Sophiris Bio

$2.70

-0.14 (-4.93%)

TLGT

Teligent

$7.36

-0.15 (-2.00%)

XNCR

Xencor

$26.00

-1.17 (-4.31%)

ZYNE

Zynerba

$13.62

-0.42 (-2.99%)

ZGNX

Zogenix

$12.70

-0.6 (-4.51%)

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 02

    Dec

  • 03

    Dec

AFMD Affimed NV
$2.15

-0.15 (-6.52%)

05/19/16
LEER
05/19/16
DOWNGRADE
Target $8
LEER
Market Perform
Affimed NV downgraded to Market Perform from Outperform at Leerink
Yesterday, Leerink analyst Michael Schmidt downgraded Affimed NV to Market Perform from Outperform, stating that the company's two clinical stage product candidates are progressing slowly while the competitive landscape intensifies. The analyst, who thinks the stock will remain range-bound, likely until 2017, set an $8 target on the shares.
04/12/16
04/12/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NetSuite (N) initiated with an Overweight at Mitsubishi UFJ by analyst Stephen Bersey, who expects the company to increase its subscription revenue by 30% in 2016 and 31% in 2017. 2. QEP Resources (QEP) initiated with an Overweight at JPMorgan with analyst Gabriel Daoud saying the company's positions in Bakken and Permian are underappreciated and can drive oil growth for years to come. 3. Rubicon Project (RUBI) initiated with a Buy at Citi by analyst Mark Kelley, who said Rubicon is his top pick in the U.S. SMID Internet space. Kelley said that the company is best positioned to benefit from programmatic growth with its full-stack offering. 4. Senseonics (SENS) initiated with a Buy at BTG and Canaccord and an Outperform at Leerink and Raymond James. 5. Affimed Therapeutics (AFMD) initiated with an Outperform at BMO Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/11/16
BMOC
04/11/16
INITIATION
Target $7
BMOC
Outperform
Affimed Therapeutics initiated with an Outperform at BMO Capital
Target $7.
08/12/16
LEER
08/12/16
DOWNGRADE
Target $3
LEER
Market Perform
Affimed NV downgraded to Market Perform from Outperform at Leerink
Leerink analyst Michael Schmidt downgraded Affimed NV to Market Perform and cut his price target for the shares to $3 from $8 following the company's Q2 results.
BPTH Bio-Path Holdings
$1.28

-0.03 (-2.29%)

04/18/16
RODM
04/18/16
INITIATION
Target $5
RODM
Buy
Bio-Path Holdings initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju started Bio-Path Holdings with a Buy rating and $5 price target.
04/18/16
04/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Allergan (AGN) initiated with a Neutral at Guggenheim. 2. Clovis (CLVS) initiated with an Outperform at Credit Suisse. 3. Corvus Pharmaceuticals (CRVS) initiated with a Buy at Guggenheim and an Outperform at Cowen and Credit Suisse. 4. Bio-Path Holdings (BPTH) initiated with a Buy at Rodman & Renshaw. 5. Broadcom Limited (AVGO) initiated with an Outperform at Cowen. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CHMA Chiasma

04/18/16
WBLR
04/18/16
DOWNGRADE
WBLR
Market Perform
Chiasma downgraded to Market Perform from Outperform at William Blair
04/18/16
WBLR
04/18/16
DOWNGRADE
Target $6
WBLR
Market Perform
Chiasma downgraded to Market Perform after Mycapssa CRL at William Blair
As previously reported, William Blair analyst Tim Lugo downgraded Chiasma to Market Perform from Outperform after the company received a Complete Response Letter related to Mycapssa capsules for the treatment of adult patients with acromegaly. However, Lugo believes the company is in a better position with regard to its European application and sees a potential MAA submission in 2019. Lugo cut his price target on the stock to $6 from $40.
04/25/16
LEHM
04/25/16
DOWNGRADE
Target $5.5
LEHM
Equal Weight
Chiasma downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Douglas Tsao downgraded Chiasma to Equal Weight citing a lack of clarity on a path forward after company received a complete response letter for its lead asset Mycapssa. Tsao cut his price target for the shares to $5.50 from $40.
04/19/16
COWN
04/19/16
DOWNGRADE
COWN
Market Perform
Chiasma downgraded to Market Perform from Outperform at Cowen
Cowen analyst Ritu Baral downgraded Chiasma to Market Perform from Outperform, citing the FDA complete response letter and the lack of clarity on the U.S. Mycapssa path going forward. The analyst, who'd previously had a $32 price target on Chiasma shares, removed her price target on the stock.
KURA Kura Oncology
$5.05

-0.3 (-5.61%)

10/13/16
LEER
10/13/16
INITIATION
Target $15
LEER
Outperform
Kura Oncology reinstated with an Outperform at Leerink
Leerink analyst Jonathan Chang resumed coverage of Kura Oncology with an Outperform rating and $15 price target, saying he views it as "attractively valued" heading into data rich 2017.
12/30/15
12/30/15
INITIATION

On the Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AVANGRID (AGR) initiated with an Outperform at Wells Fargo...Agile Therapeutics (AGRX) initiated with a Buy at Noble Financial...Energen (EGN) initiated with an Equal Weight at Stephens Generac (GNRC) initiated with a Neutral at Northcoast...Healthstream (HSTM) initiated with a Neutral at Sidoti...Kura Oncology (KURA) initiated with an Outperform at Oppenheimer...Performance Sports Group (PSG) initiated with an Outperform at Oppenheimer...Skullcandy (SKUL) initiated with an Outperform at Oppenheimer.
01/22/16
JMPS
01/22/16
INITIATION
Target $24
JMPS
Outperform
Kura Oncology initiated with an Outperform at JMP Securities
JMP Securities analyst Michael King started Kura Oncology with an Outperform rating and $24 price target.
01/22/16
01/22/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: CVS Health (CVS) initiated with an Outperform at Baird... Cognex (CGNX) initiated with an Outperform at Raymond James... Ctrip.com (CTRP) initiated with a Buy at Nomura... First Industrial Realty (FR) initiated with a Buy at Jefferies... Kura Oncology (KURA) initiated with an Outperform at JMP Securities... Matador (MTDR) initiated with an Outperform at Iberia... NetEase (NTES) initiated with a Neutral at Nomura... Praxair (PX) reinstated with an Underperform at BofA/Merrill... Primerica (PRI) initiated with an Outperform at William Blair... Prologis (PLD) initiated with a Hold at Jefferies... RAIT Financial (RAS) initiated with an Outperform at FBR Capital... STAG Industrial (STAG) initiated with a Hold at Jefferies... SolarCity (SCTY) initiated with an Overweight at Barclays... Sprouts Farmers Markets (SFM) initiated with an Outperform at Wells Fargo... Sunrun (RUN) initiated with an Overweight at Barclays... Terreno Realty (TRNO) initiated with a Hold at Jefferies... Tower Semiconductor (TSEM) initiated with a Strong Buy at Needham... Unique Fabricating (UFAB) initiated with a Buy at B. Riley... Walgreens Boots Alliance (WBA) initiated with an Outperform at Baird.
EIGR Eiger BioPharmaceuticals
$12.50

-0.5 (-3.85%)

07/05/16
OPCO
07/05/16
INITIATION
Target $34
OPCO
Outperform
Eiger BioPharmaceuticals initiated with an Outperform at Oppenheimer
Oppenheimer analyst Carlos Solorzano started Eiger BioPharmaceuticals with an Outperform rating and $34 price target.
08/18/16
PIPR
08/18/16
NO CHANGE
Target $35
PIPR
Overweight
Eiger BioPharma raises $20M ahead of Sarasar Data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says that Eiger BioPharmaceuticals ended Q2 with $45.4M and just issued 1.25 million shares at $16.00, raising gross proceeds of $20M, which will fund development of multiple Phase 2 orphan disease candidates into 2018. Tenthoff notes that he is looking for important Phase 2 updates on Sarasar, or lonafarnib, in Hepatitis Delta Virus at AASLD, or American Association for the study of liver diseases, meeting in November. The analyst reiterates an Overweight rating on the stock but lowered his price target on the shares to $35 from $37.50 to account for dilution from the deal.
09/13/16
PIPR
09/13/16
NO CHANGE
Target $35
PIPR
Overweight
Piper sees a trading opportunity in Eiger BioPharmaceuticals
Piper Jaffray analyst Edward Tenthoff believes the recent weakness in shares of Eiger BioPharmaceuticals has created a "compelling trading opportunity" into November's American Association for the Study of Liver Diseases meeting. Eiger will report 24-week Phase II data on Sarasar to treat Hepatitis Delta Virus at the conference, Tenthoff tells investors in a research note. The analyst expects the data to be "highly informative about future development of Sarasar." He reiterates an Overweight rating on Eiger shares with a $35 price target.
06/01/16
WEDB
06/01/16
INITIATION
Target $36
WEDB
Outperform
Eiger BioPharmaceuticals initiated with an Outperform at Wedbush
Target $36.
MRNS Marinus Pharmaceuticals
$1.11

-0.05 (-4.31%)

06/20/16
LEER
06/20/16
NO CHANGE
Target $66
LEER
Outperform
Leerink remains positive on SAGE Therapeutics ahead of data catalysts
After meeting with SAGE Therapeutics' (SAGE) CEO Jeff Jonas and CFO Kimi Iguchi, Leerink analyst Paul Matteis says he continues to see a positive risk and reward for the company's stock ahead of multiple near-term data catalysts. Additionally, the analyst says he views the recent failure of Marinus Pharmaceuticals' (MRNS) ganaxolone in focal onset seizures as likely due to a bioavailability issue, not a mechanistic deficiency, and thus shouldn't read negatively on the potential of SAGE Therapeutics' SAGE-217. Matteis reiterates an Outperform rating and $66 price target on SAGE's shares.
06/14/16
RBCM
06/14/16
DOWNGRADE
RBCM
Sector Perform
Marinus Pharmaceuticals downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Marinus after the company announced that its first Phase 3 epilepsy study for adult focal onset seizures failed to meet its primary endpoint. Target to $2 from $14.
06/14/16
JEFF
06/14/16
NO CHANGE
Target $2.5
JEFF
Buy
Marinus price target lowered to $2.50 from $13 at Jefferies
Jefferies analyst Brian Abrahams cut his price target for Marinus Pharmaceuticals to $2.50 from $13 after ganaxolone failed in a late-stage seizure study. The analyst, however, still sees residual value for the company given ganaxolone evidence of activity and consistent on-target safety profile. He thinks shares could rebound to $2.50 and keeps a Buy rating on Marinus.
09/30/16
JMPS
09/30/16
NO CHANGE
JMPS
Marinus Pharmaceuticals data positive, says JMP Securities
JMP Securities analyst Jason Butler says that a trial of Marinus' ganaxolone PCDH19 in female pediatric eplilepsy yielded "promising" results. The analyst says that the data is positive, while female pediatric eplilepsy is an unmet need. Butler keeps a $5 price target and Outperform rating on the shares.
NERV Minerva
$13.55

-0.45 (-3.21%)

05/12/16
JEFF
05/12/16
INITIATION
Target $10
JEFF
Buy
Minerva assumed with a Buy at Jefferies
Jefferies analyst Chris Howerton assumed coverage of Minerva with a Buy rating and $10 price target.
10/18/16
JMPS
10/18/16
NO CHANGE
JMPS
Minerva poised to report positive data, says JMP Securities
JMP Securities analyst Jason Butler expects Phase 2b data on Minerva's MIN-101 drug for schizophrenia to be positive when it's reported this month. The analyst thinks that the data could include evidence that the drug "maintains control of positive symptoms." He reiterates a $17 price target and Outperform rating on the shares.
05/26/16
JMPS
05/26/16
NO CHANGE
Target $17
JMPS
Outperform
Minerva price target raised to $17 from $10 at JMP Securities
JMP Securities analyst Jason Butler raised his price target for Minerva Neurosciences to $17 from $10 after the company's schizophrenia treatment met its endpoint in a Phase IIb study. The analyst has an Outperform rating on the shares. Minerva is trading up 176%, or $6.23, to $9.77 in afternoon trading.
OVAS OvaScience
$3.58

-0.19 (-5.04%)

01/25/16
01/25/16
DOWNGRADE

On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Eagle (AEO) downgraded to Hold from Buy at BB&T... American Express (AXP) downgraded on weak revenue outlook at Argus... Bristol-Myers (BMY) downgraded to Market Perform from Outperform at BMO Capital... Caterpillar (CAT) downgraded to Sell from Neutral at Goldman... Crestwood Equity (CEQP) downgraded to Neutral on potential distribution cut at Baird... Cummins (CMI) downgraded to Neutral from Buy at Citi... Federal Realty (FRT) downgraded to Hold from Buy at Evercore ISI... GKN PLC (GKNLY) downgraded to Neutral from Outperform at Credit Suisse... Galapagos NV (GLPG) downgraded to Neutral from Buy at GoldmanvHortonworks (HDP) downgraded to Perform from Outperform at Oppenheimer... International Flavors (IFF) downgraded on headwinds at Stifel... International Paper (IP) downgraded to Neutral from Buy at Citi... JPMorgan (JPM) downgraded to Neutral from Buy at Nomura... KapStone (KS) downgraded to Underperform from Neutral at Macquarie... Mosaic (MOS) downgraded to Neutral from Overweight at JPMorgan... NetSuite (N) downgraded to Equal Weight from Overweight at Stephens... ONEOK Partners (OKS) downgraded to Neutral at Baird... OvaScience (OVAS) downgraded to Perform from Outperform at Oppenheimer... Packaging Corp. (PKG) downgraded to Neutral from Buy at Citi... Potash (POT) downgraded to Neutral from Overweight at JPMorgan... Power Solutions (PSIX) downgraded to Neutral from Overweight at Piper Jaffray... Raymond James (RJF) downgraded to Neutral from Buy at Nomura... Regeneron (REGN) downgraded to Sell from Neutral at Chardan... SanDisk (SNDK) downgraded to Underperform from Outperform at CLSA... Toll Brothers (TOL) downgraded to Market Perform from Outperform at JMP Securities... Twitter (TWTR) downgraded to Hold from Buy at Stifel... WPX Energy (WPX) downgraded to Sector Perform from Outperform at Iberia... WestRock (WRK) downgraded to Neutral from Buy at BofA/Merrill... Whole Foods (WFM) downgraded to Underperform from Market Perform at BMO Capital... Zurich Insurance (ZURVY) downgraded to Neutral from Outperform at Exane BNP Paribas.
01/20/16
FBCO
01/20/16
INITIATION
Target $7
FBCO
Underperform
OvaScience initiated with an Underperform at Credit Suisse
Credit Suisse analyst Kennen MacKay started OvaScience with an Underperform rating and $7 price target.
01/25/16
OPCO
01/25/16
DOWNGRADE
OPCO
Perform
OvaScience downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Rohit Vanjani downgraded OvaScience to Perform saying realizing the opportunity for the company's first launched technology, AUGMENT, may take some time. AUGMENT traction may continue to be challenged in 2016, Vanjani tells investors in a research note.
01/21/16
01/21/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3M (MMM) initiated with a Buy at Citi... AMAG Pharmaceuticals (AMAG) initiated with an Equal Weight at Barclays... Acceleron (XLRN) initiated with an Outperform at Credit Suisse... Agios Pharmaceuticals (AGIO) initiated with an Outperform at Credit Suisse... Akebia (AKBA) initiated with a Neutral at Credit Suisse... CIT Group (CIT) initiated with a Hold at Deutsche Bank... Check Point (CHKP) initiated with a Neutral at Cleveland Research... Clovis (CLVS) initiated with an Outperform at Credit Suisse... Colfax (CFX) initiated with a Sell at Citi... Danaher (DHR) initiated with a Neutral at Citi... Dover (DOV) initiated with a Neutral at Citi... Emerson (EMR) initiated with a Sell at Citi... Endo (ENDP) initiated with an Equal Weight at Barclays... Endocyte (ECYT) initiated with an Outperform at Credit Suisse... FibroGen (FGEN) initiated with a Neutral at Credit Suisse... FireEye (FEYE) initiated with an Outperform at Northland... Five Prime (FPRX) initiated with an Outperform at Credit Suisse... Flowserve (FLS) initiated with a Neutral at Citi... General Electric (GE) initiated with a Buy at Citi... Honeywell (HON) initiated with a Buy at Citi... Ignyta (RXDX) initiated with an Outperform at Credit Suisse... Illinois Tool Works (ITW) initiated with a Buy at Citi... Imperva (IMPV) initiated with an Outperform at Northland... Ingersoll-Rand (IR) initiated with a Buy at Citi... Joint Corp. (JYNT) initiated with a Buy at Maxim... M&T Bank (MTB) resumed with a Neutral at JPMorgan... Medivation (MDVN) initiated with an Outperform at Credit Suisse... Newfield Exploration (NFX) initiated with an Outperform at Imperial Capital... OvaScience (OVAS) initiated with an Underperform at Credit Suisse... PFSweb (PFSW) initiated with a Buy at Canaccord... Palo Alto (PANW) initiated with an Outperform at Northland... Perrigo (PRGO) initiated with an Overweight at Barclays... Prothena (PRTA) initiated with an Outperform at Credit Suisse... Puma Biotechnology (PBYI) initiated with an Outperform at Credit Suisse... Rockwell Automation (ROK) initiated with a Neutral at Citi... Seattle Genetics (SGEN) initiated with an Outperform at Credit Suisse... Shopify (SHOP) initiated with an Outperform at Wedbush... Square (SQ) initiated with a Market Perform at William Blair... TESARO (TSRO) initiated with an Outperform at Wedbush... Tyco (TYC) initiated with a Neutral at Citi... Ultragenyx (RARE) initiated with an Outperform at Credit Suisse.
SCLN SciClone
$10.25

0.05 (0.49%)

11/29/16
MAXM
11/29/16
INITIATION
Target $14
MAXM
Buy
SciClone initiated with a Buy at Maxim
Maxim analyst Gabrielle Zhou initiated SciClone with a Buy rating and $14 price target, calling it uniquely positioned as a significant specialty pharma player in the China market.
SPHS Sophiris Bio
$2.70

-0.14 (-4.93%)

08/30/16
PIPR
08/30/16
INITIATION
Target $7
PIPR
Overweight
Sophiris Bio initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Charles Duncan started Sophiris Bio with an Overweight rating and $7 price target.
09/15/16
ROTH
09/15/16
INITIATION
Target $8
ROTH
Buy
Sophiris Bio initiated with a Buy at Roth Capital
Roth Capital analyst Joseph Pantginis started Sophiris Bio with a Buy and $8 price target. The analyst believes the company's lead asset, PRX302, has the potential to address the large markets of benign prostate hyperplasia with a positive Phase 3 in hand and localized prostate cancer.
TLGT Teligent
$7.36

-0.15 (-2.00%)

06/22/16
RAJA
06/22/16
INITIATION
Target $11
RAJA
Strong Buy
Teligent initiated with a Strong Buy at Raymond James
Raymond James analyst Elliot Wilbur initiated Teligent with a Strong Buy and $11 price target. The analyst believes the company is poised for a major growth spurt powered by its TICO product development and selection strategy that has resulted in the assembly of an enriched pipeline of long duration growth assets in high barrier to entry generic markets.
XNCR Xencor
$26.00

-1.17 (-4.31%)

06/29/16
LEER
06/29/16
NO CHANGE
Target $26
LEER
Outperform
Xencor price target raised to $26 from $18 at Leerink
Leerink analyst Michael Schmidt raised his price target for Xencor to $26 from $18 to reflect the impact on cash and economics of the announced collaboration with Novartis (NVS) to develop two bispecific T cell recruiting antibodies for the treatment of acute myeloid leukemia and B-cell malignancies. Schmidt reiterates an Outperform rating on Xencor's shares.
10/04/16
PIPR
10/04/16
INITIATION
Target $35
PIPR
Overweight
Xencor initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff started Xencor with an Overweight rating and $35 price target. The analyst views the company's next-gen and bispecific antibodies as "exciting."
12/22/15
12/22/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AVANGRID (AGR) initiated with a Neutral at JPMorgan... Accuray (ARAY) initiated with a Sector Perform at RBC Capital... American Express (AXP) initiated with a Market Perform at JMP Securities... BioTime (BTX) initiated with an Outperform at Oppenheimer... Biota Pharmaceuticals (BOTA) initiated with an Outperform at FBR Capital... Box (BOX) initiated with an Outperform at JMP Securities... CNO Financial (CNO) initiated with an Outperform at Raymond James... Capital One (COF) initiated with a Hold at Evercore ISI... Criteo (CRTO) initiated with a Buy at SunTrust... CyberArk (CYBR) initiated with a Hold at Evercore ISI... CyrusOne (CONE) initiated with an Overweight at JPMorgan... Digital Realty (DLR) initiated with a Neutral at JPMorgan... Discover (DFS) initiated with a Hold at Evercore ISI... Etsy (ETSY) initiated with a Sell at Roth Capital... Fenix Parts (FENX) initiated with a Buy at Roth Capital... Fibrocell Science (FCSC) initiated with a Buy at Roth Capital... Franklin Electric (FELE) initiated with a Sell at Ladenburg... Harman (HAR) initiated with a Neutral at Susquehanna... Karyopharm (KPTI) initiated with a Buy at Canaccord... MPLX (MPLX) initiated with a Neutral at Credit Suisse... Marchex (MCHX) initiated with a Buy at Roth Capital... NantKwest (NK) initiated with a Buy at Canaccord... Nexstar (NXST) initiated with an Outperform at Barrington... Orbital ATK (OA) initiated with a Buy at CL King... Perrigo (PRGO) initiated with an Outperform at Northland... QTS Realty Trust (QTS) initiated with an Overweight at JPMorgan... RPC, Inc. (RES) initiated with a Buy at Guggenheim... Rubicon Project (RUBI) initiated with a Buy at SunTrust... Sorrento Therapeutics (SRNE) initiated with an Outperform at FBR Capital... Travelport (TVPT) initiated with a Neutral at SunTrust... TubeMogul (TUBE) initiated with a Buy at SunTrust... Ultragenyx (RARE) initiated with a Buy at Canaccord... Varian Medical (VAR) initiated with a Sector Perform at RBC Capital... Wayfair (W) initiated with a Neutral at SunTrust... Xencor (XNCR) initiated with a Buy at Canaccord.
11/28/16
ADAM
11/28/16
NO CHANGE
Target $32
ADAM
Buy
Xencor price target raised to $32 from $27 at Canaccord
Canaccord analyst Arlinda Lee raised her price target on Xencor to $32 from $27 citing its XmAb pipeline and attractive bispecifics capabilities and the company's mechanistic rationale for treating IgG4-RD with XmAb5871. Lee reiterated her Buy rating on Xencor shares.
ZYNE Zynerba
$13.62

-0.42 (-2.99%)

10/07/16
HCWC
10/07/16
INITIATION
Target $22
HCWC
Buy
Zynerba initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Zynerba Pharmaceuticals with a Buy rating and $22 price target.
11/15/16
ROTH
11/15/16
NO CHANGE
Target $25
ROTH
Buy
Zynerba should be bought ahead of Phase 2 read-outs, says Roth Capital
Roth Capital analyst Michael Higgins notes that Zynerba Q3 was generally in line, as enrollment continues in two Phase 2 trials, with enrollment expected to begin in a third Phase 2 before year-end. The analyst believes the company is well-capitalized, with cash sufficient to fund operations into 2018, and encourages investors to accumulate a position in Zynerba ahead of three Phase 2 read-outs from its ZYN002 in the first half of 2017. He reiterates a Buy rating and $25 price target on the shares.
03/17/16
ROTH
03/17/16
INITIATION
Target $25
ROTH
Buy
Zynerba initiated with a Buy at Roth Capital
Roth Capital analyst Michael Higgins started Zynerba Pharmaceuticals with a Buy rating and $25 price target.
ZGNX Zogenix
$12.70

-0.6 (-4.51%)

10/04/16
LEER
10/04/16
INITIATION
Target $17
LEER
Outperform
Zogenix reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of Zogenix with an Outperform rating and $17 price target.
05/05/16
LEER
05/05/16
NO CHANGE
LEER
Outperform
Zogenix drug showing 'encouraging efficacy' across seizure types, says Leerink
Leerink analyst Paul Matteis believes that the median seizure reduction demonstrated by Zogenix's (ZGNX) ZX008 compares favorably to the reduction in convulsive seizures seen in the placebo arm of the recent GW Pharmaceuticals (GWPH) Epidiolex phase 3 Dravet study, though he noted that Zogenix data represents a small sample and was generated at a single clinical site. Still, the new data continues to reflect ZX008's "encouraging efficacy across various types of motor seizures" and the drug's safety data also look favorable, Matteis tells investors. The firm keeps an Outperform rating on Zogenix shares.
11/11/16
AGIS
11/11/16
INITIATION
Target $28
AGIS
Buy
Zogenix initiated with a Buy at Aegis
Target $28.

TODAY'S FREE FLY STORIES

VNCE

Vince Holding

$4.55

0.35 (8.33%)

20:25
12/07/16
12/07
20:25
12/07/16
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

NWBO

Northwest Biotherapeutics

$0.55

0.0227 (4.33%)

20:17
12/07/16
12/07
20:17
12/07/16
20:17
Hot Stocks
Northwest Biotherapeutics to delist from Nasdaq, confirms clinical trial plans »

Northwest Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$111.03

1.08 (0.98%)

, MSFT

Microsoft

$61.37

1.42 (2.37%)

20:07
12/07/16
12/07
20:07
12/07/16
20:07
Periodicals
NHL in negotiations to bring Apple devices to team benches, TSN says »

The NHL has told teams it…

AAPL

Apple

$111.03

1.08 (0.98%)

MSFT

Microsoft

$61.37

1.42 (2.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 13

    Mar

ATKR

Atkore

$19.71

-0.11 (-0.55%)

19:59
12/07/16
12/07
19:59
12/07/16
19:59
Syndicate
Atkore 8M share Secondary priced at $19.00 »

Credit Suisse, Deutsche…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$26.20

-2.23 (-7.84%)

19:58
12/07/16
12/07
19:58
12/07/16
19:58
Syndicate
Blueprint Medicines 5M share Secondary priced at $25.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

LULU

lululemon

$59.84

2.6 (4.54%)

19:50
12/07/16
12/07
19:50
12/07/16
19:50
Hot Stocks
lululemon CFO says early Q4 trends strengthened into December »

Speaking during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

LULU

lululemon

$59.84

2.6 (4.54%)

19:50
12/07/16
12/07
19:50
12/07/16
19:50
Hot Stocks
lululemon CEO highlights Q3 gross margin, reports 11% comp growth in pants »

Speaking during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

CVX

Chevron

$114.44

1.68 (1.49%)

19:20
12/07/16
12/07
19:20
12/07/16
19:20
Hot Stocks
Chevron announces $19.8B capital, exploratory budget for 2017 »

Chevron announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

X

U.S. Steel

$37.49

1.54 (4.28%)

18:49
12/07/16
12/07
18:49
12/07/16
18:49
Periodicals
U.S. Steel CEO: Company may bring back 10,000 U.S. jobs, CNBC says »

U.S. Steel could bring…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNDA

Vanda

$15.40

-0.6 (-3.75%)

18:47
12/07/16
12/07
18:47
12/07/16
18:47
Hot Stocks
Vanda settles Fanapt patent litigation with Apotex »

Vanda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AE

Adams Resources

$42.31

-0.68 (-1.58%)

, SWN

Southwestern Energy

$12.37

-0.08 (-0.64%)

18:46
12/07/16
12/07
18:46
12/07/16
18:46
Hot Stocks
Adams Resources appoints Josh Anders as CFO »

Adams Resources &…

AE

Adams Resources

$42.31

-0.68 (-1.58%)

SWN

Southwestern Energy

$12.37

-0.08 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EZPW

EZCORP

$11.80

0.05 (0.43%)

18:42
12/07/16
12/07
18:42
12/07/16
18:42
Earnings
EZCORP reports Q4 EPS with items (31c), may not compare to consensus 6c »

EPS figure includes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

RICE

Rice Energy

$24.59

-0.16 (-0.65%)

18:33
12/07/16
12/07
18:33
12/07/16
18:33
Initiation
Rice Energy initiated  »

Rice Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$770.42

5.7 (0.75%)

18:30
12/07/16
12/07
18:30
12/07/16
18:30
Periodicals
Amazon spokesperson denies 2,000 grocery stores report, CNET says »

Following a report by the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICON

Iconix Brand

$9.26

0.14 (1.54%)

18:23
12/07/16
12/07
18:23
12/07/16
18:23
Hot Stocks
Iconix Brand reports employment termination of Chief Strategy Officer Blumberg »

Iconix Brand disclosed in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBYI

Puma Biotechnology

$39.80

-2 (-4.78%)

18:23
12/07/16
12/07
18:23
12/07/16
18:23
Hot Stocks
Puma Biotechnology 'pleased' to complete biomarker analysis of neratinib »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTK

Flotek

$11.10

-2.01 (-15.33%)

18:17
12/07/16
12/07
18:17
12/07/16
18:17
Hot Stocks
Flotek: Reviewing FourWorld Capital short report, remain confident in product »

Speaking earlier during…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PBYI

Puma Biotechnology

$39.80

-2 (-4.78%)

18:09
12/07/16
12/07
18:09
12/07/16
18:09
Hot Stocks
Puma Biotechnology 'pleased' with preliminary neratinib activity »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNM

PNM Resources

$32.05

0.45 (1.42%)

18:09
12/07/16
12/07
18:09
12/07/16
18:09
Hot Stocks
PNM Resources requests an electric rate increase of $99M in New Mexico »

PNM Resources' New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

BK

BNY Mellon

$48.55

0.56 (1.17%)

18:03
12/07/16
12/07
18:03
12/07/16
18:03
Periodicals
BNY Mellon outage led to certain Swift payment failures, WSJ reports »

Bank of New York Mellon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRD

Tailored Brands

$18.93

0.62 (3.39%)

17:52
12/07/16
12/07
17:52
12/07/16
17:52
Hot Stocks
Tailored Brands up 22% to $23.20 after Q3 results beat estimates »

The company also raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

FLXS

Flexsteel Industries

$59.12

2.92 (5.20%)

, UNH

UnitedHealth

$159.40

2.08 (1.32%)

17:50
12/07/16
12/07
17:50
12/07/16
17:50
Hot Stocks
Flexsteel names Eric Rangen chair of the board »

Flexsteel Industries…

FLXS

Flexsteel Industries

$59.12

2.92 (5.20%)

UNH

UnitedHealth

$159.40

2.08 (1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$52.10

1.53 (3.03%)

, UA

Under Armour

$27.03

1.62 (6.38%)

17:49
12/07/16
12/07
17:49
12/07/16
17:49
Periodicals
Nike losing market share to faster-growing rivals, Barron's reports »

Despite being down nearly…

NKE

Nike

$52.10

1.53 (3.03%)

UA

Under Armour

$27.03

1.62 (6.38%)

ADDYY

adidas

$76.96

1.225 (1.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

T

AT&T

$40.45

1.1 (2.80%)

17:45
12/07/16
12/07
17:45
12/07/16
17:45
Conference/Events
AT&T management to meet with Jefferies »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

EFC

Ellington Financial

$16.30

0.2 (1.24%)

17:41
12/07/16
12/07
17:41
12/07/16
17:41
Hot Stocks
Ellington Financial reports estimated book value per share $19.80 as of Nov 30 »

Ellington Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.